Adjuvant hyperthermic intraperitoneal chemotherapy in patients with colon cancer at high risk of peritoneal metastases: individual patient data meta-analysis - Scorecard - MDSpire

Adjuvant hyperthermic intraperitoneal chemotherapy in patients with colon cancer at high risk of peritoneal metastases: individual patient data meta-analysis

  • By

  • Julie J M Hamm

  • Rudolf van den Berg

  • Eleni-Rosalina Andrinopoulou

  • E Sophie Zwanenburg

  • Gijsbert D Musters

  • Pieter J Tanis

  • Alvaro Arjona-Sanchez

  • the COLOPEC and HIPECT4 Collaborator Groups

  • E S Zwanenburg

  • C E L Klaver

  • D D Wisselink

  • C J A Punt

  • P Snaebjornsson

  • J Crezee

  • A G J Aalbers

  • A R M Brandt-Kerkhof

  • A J A Bremers

  • J W A Burger

  • H F J Fabry

  • F T J Ferenschild

  • S Festen

  • W M U van Grevenstein

  • P H J Hemmer

  • I H J T de Hingh

  • N F M Kok

  • M Kusters

  • L Schoonderwoerd

  • J B Tuynman

  • A W H van de Ven

  • H L van Westreenen

  • M J Wiezer

  • D D E Zimmerman

  • A van Zweeden

  • M G W Dijkgraaf

  • G D Musters

  • M Ortega-Salas Rosa

  • A Martínez-López

  • E M Torres-Tordera

  • B Rufian-Andujar

  • F Valenzuela-Molina

  • A Gordon-Suarez

  • F J Medina-Fernandez

  • A Gomez-España

  • F Triviño-Tarradas

  • M Granados-Rodríguez

  • M C Vazquez-Borrego

  • M Garzas-Martin Almagro

  • I Inmaculada Lasa-Unzué

  • R Gómez-Sanz

  • A López-García

  • M Díez-Alonso

  • P Hernández-Juara

  • R Molina-Villaverde

  • C Castillo Torres

  • J I Busteros Moraza

  • J J Segura-Sampedro

  • R Rafael Morales-Soriano

  • C Pineño-Flores

  • A Serrano Del Moral

  • I Manzanedo

  • F Pereira

  • M E Moneva Arce

  • R Gianchandani-Moorjani

  • J M Sánchez-González

  • C Díaz-López

  • G Hernandez Hernandez

  • J G Diaz Mejias

  • M J Hernández Barroso

  • R M Abreu-Falcon

  • A Muñoz Hernández

  • V Castro López Taruella

  • C Hernandez Pérez

  • R Afonso

  • M Viña-Romero

  • R Perez-Rodriguez

  • M Heras-Garceau

  • I Ramos

  • O Crusellas Maña

  • M A Lorenzo Liñán

  • P A Parra Baños

  • M Carrasco Prats

  • M Ruiz Marín

  • E Terol Garaulet

  • F García Molina

  • I M Gallarín Salamanca

  • M González Cordero

  • A Titos García

  • S González-Moreno

  • A Mayol Oltra

  • April 29, 2025

  • 0 min

Share

Clinical Scorecard: Efficacy of Adjuvant Hyperthermic Intraperitoneal Chemotherapy in High-Risk Colon Cancer Patients: A Meta-Analysis of Individual Patient Data

At a Glance

CategoryDetail
ConditionLocally advanced colon cancer (pT4) with risk of locoregional recurrence including peritoneal metastases
Key MechanismsAdjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) aims to reduce locoregional recurrence by delivering heated chemotherapy directly into the peritoneal cavity after surgery
Target PopulationPatients with locally advanced colon cancer, particularly those with right-sided tumours
Care SettingPostoperative adjuvant treatment setting combined with systemic chemotherapy

Key Highlights

  • Adjuvant HIPEC significantly reduced locoregional recurrence in patients with right-sided locally advanced colon cancer (HR 0.56, P < 0.001).
  • No significant reduction in locoregional recurrence was observed in the overall population receiving HIPEC versus control (16.0% vs 21.2%, P = 0.295).
  • No significant differences in disease-free survival or overall survival were found; longer follow-up is needed for definitive conclusions.

Guideline-Based Recommendations

Diagnosis

  • Identify patients with locally advanced colon cancer (pT4) at high risk for peritoneal metastases, including right-sided tumour location.

Management

  • Consider adjuvant HIPEC combined with systemic chemotherapy to reduce locoregional recurrence in patients with right-sided locally advanced colon cancer.
  • Continue standard adjuvant systemic chemotherapy as per current protocols.

Monitoring & Follow-up

  • Monitor patients postoperatively for locoregional recurrence with regular follow-up and imaging.
  • Long-term follow-up is necessary to assess disease-free and overall survival outcomes.

Risks

  • Potential risks and adverse effects of HIPEC should be weighed against benefits; current data do not show survival benefit in overall population.
  • Further research is needed to clarify long-term safety and efficacy.

Patient & Prescribing Data

386 patients with locally advanced colon cancer from two RCTs (COLOPEC and HIPECT4), median follow-up 36 months

HIPEC reduced locoregional recurrence significantly in right-sided tumours but not in left-sided or overall population; no survival benefit demonstrated yet

Clinical Best Practices

  • Select patients carefully for adjuvant HIPEC based on tumour location and risk factors.
  • Combine HIPEC with standard systemic chemotherapy for optimal locoregional control in right-sided colon cancer.
  • Ensure multidisciplinary discussion and informed consent regarding potential benefits and uncertainties of HIPEC.
  • Maintain rigorous postoperative surveillance to detect recurrence early.
  • Support further clinical trials and longer follow-up to establish survival impact.

References

Original Source(s)

Adjuvant hyperthermic intraperitoneal chemotherapy in patients with colon cancer at high risk of peritoneal metastases: individual patient data meta-analysis

  • by Julie J M Hamm, Rudolf van den Berg, Eleni-Rosalina Andrinopoulou, E Sophie Zwanenburg, Gijsbert D Musters, Pieter J Tanis, Alvaro Arjona-Sanchez, the COLOPEC and HIPECT4 Collaborator Groups, E S Zwanenburg, C E L Klaver, D D Wisselink, C J A Punt, P Snaebjornsson, J Crezee, A G J Aalbers, A R M Brandt-Kerkhof, A J A Bremers, J W A Burger, H F J Fabry, F T J Ferenschild, S Festen, W M U van Grevenstein, P H J Hemmer, I H J T de Hingh, N F M Kok, M Kusters, L Schoonderwoerd, J B Tuynman, A W H van de Ven, H L van Westreenen, M J Wiezer, D D E Zimmerman, A van Zweeden, M G W Dijkgraaf, G D Musters, M Ortega-Salas Rosa, A Martínez-López, E M Torres-Tordera, B Rufian-Andujar, F Valenzuela-Molina, A Gordon-Suarez, F J Medina-Fernandez, A Gomez-España, F Triviño-Tarradas, M Granados-Rodríguez, M C Vazquez-Borrego, M Garzas-Martin Almagro, I Inmaculada Lasa-Unzué, R Gómez-Sanz, A López-García, M Díez-Alonso, P Hernández-Juara, R Molina-Villaverde, C Castillo Torres, J I Busteros Moraza, J J Segura-Sampedro, R Rafael Morales-Soriano, C Pineño-Flores, A Serrano Del Moral, I Manzanedo, F Pereira, M E Moneva Arce, R Gianchandani-Moorjani, J M Sánchez-González, C Díaz-López, G Hernandez Hernandez, J G Diaz Mejias, M J Hernández Barroso, R M Abreu-Falcon, A Muñoz Hernández, V Castro López Taruella, C Hernandez Pérez, R Afonso, M Viña-Romero, R Perez-Rodriguez, M Heras-Garceau, I Ramos, O Crusellas Maña, M A Lorenzo Liñán, P A Parra Baños, M Carrasco Prats, M Ruiz Marín, E Terol Garaulet, F García Molina, I M Gallarín Salamanca, M González Cordero, A Titos García, S González-Moreno, A Mayol Oltra

  • April 29, 2025

Related Content

Laparoscopic radical right hemicolectomy with CME, CVL and division of right gastroepiploic vessels

The impact of body mass index on prognosis in patients with colon carcinoma

Overall survival after resection for colon cancer in a national cohort study was adversely affected by TNM stage, lymph node ratio, gender, and old age